Compare NRG Energy Inc (NRG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NRG Energy Inc trades at $132.3 (market cap $27.55B), while State Street SPDR S&P Biotech ETF trades at $154.32. The key difference: NRG Energy Inc pays a 1.46% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NRG Energy Inc nearer its low. Which is the better fit depends on your goals.
| NRG | XBI | |
|---|---|---|
Market Cap | $27.55B | — |
Sector | Utilities | Broad Market / Factor |
52-Week High | $184.03 | $164.28 |
52-Week Low | $120.65 | $85.16 |
Enterprise Value | $51.38B | — |
Dividend Yield | 1.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $131.60, up 1.93% over 24 hours, with a bearish technical signal despite bullish oscillators. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Revenue grew to $30.71 billion in 2025, though net income margin remains thin at 0.74%. Analyst consensus is strongly bullish with a $217.50 price target, supported by institutional buying interest.
The outlook is cautiously optimistic given strong analyst support and strategic positioning for power demand growth, but risks include volatile cash flows, high debt levels, and execution challenges. The stock offers potential upside if earnings momentum improves, yet investors face headwinds from margin pressure and macroeconomic sensitivity.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
